The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis

American Journal of Epidemiology

Volumn 173, Issue 1, 2011, Pages 84-93

  Landrum, Michael L ^a,b   Hullsiek, Katherine Huppler ^a,c   Chun, Helen M ^d   Crum Cianflone, Nancy F ^a,d   Ganesan, Anuradha ^a,e   Weintrob, Amy C ^a,e   Barthel, R Vincent ^f   O'Connell, Robert J ^a,g   Agan, Brian K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

hepatitis B vaccines; hepatitis B virus; HIV; immunization; vaccination

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

COHORT ANALYSIS; HEALTH RISK; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; NUMERICAL MODEL; PARTICIPATORY APPROACH; VACCINATION; VIRAL DISEASE;

ADULT; ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE;

ADULT; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

UNITED STATES;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 78650463585     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq326     Document Type: Article

References (30)

1. Chun HM, Fieberg AM, Hullsiek KH, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50(3): 426-436.
2. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571-577.
3. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003;23(2):125-136.
4. Homann C, Krogsgaard K, Pedersen C, et al. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr. 1991;4(4):416-420.
5. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29(4):1306-1310.
6. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-1926.
7. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-hepatitis B virus international panel. AIDS. 2008;22(12): 1399-1410.
8. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clin Infect Dis. 2008;47(11):1468-1475.
9. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
10. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
11. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55 (RR-16):1-33.
12. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317-322, 327-328.
13. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40 (RR-13):1-25.
14. Department of Immunization, Vaccines and Biologicals, World Health Organization. WHO Vaccine-Preventable Diseases: Monitoring System- 2008 Global Summary. Geneva, Switzerland: World Health Organization; 2008. ( http://whqlibdoc.who.int/hq/2008/WHO-IVB-2008-eng.pdf). (Accessed May 27, 2009).
15. Hepatitis B vaccination coverage among adults- United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(18): 509-511.
16. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS. 2010;24(4):545-555.
17. Sun HY, Ko WC, Tsai JJ, et al. Seroprevalence of chronic hepatitis B virus infection among Taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol. 2009; 104(4):877-884.
18. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5): 333-341.
19. Landrum ML, Fieberg AM, Chun HM, et al. The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults. PLoS One. 2010;5(1):e8687. (doi: 10.1371/journal.pone.0008687).
20. Castro KG, Ward JW, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
21. Hullsiek KH, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics. 2002;3(2):179-193.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
23. Landrum ML, Huppler Hullsiek K, Ganesan A, et al. Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27(34): 4731-4738.
24. Hadler SC, Francis DP, Maynard JE, et al. Long-term immu-nogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315(4):209-214.
25. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303(15):833-841.
26. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis. 1989;160(5):766-769.
27. Schiller JS, Euler GL. Vaccination Coverage Estimates From the National Health Interview Survey: United States, 2008. Hyattsville, MD: National Center for Health Statistics; 2009. (http://www.cdc.gov/nchs/data/hestat/vaccine- coverage/vaccine-coverage.pdf). (Accessed March 9, 2010).
28. Scott PT, Niebuhr DW, McGready JB, et al. Hepatitis B immunity in United States military recruits. J Infect Dis. 2005; 191(11):1835-1841.
29. Brodine SK, Starkey MJ, Shaffer RA, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17(17):2521-2527.
30. Overton ET, Sungkanuparph S, Powderly WG, et al. Unde-tectable HIV plasma RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005; 41(7):1045-1048.